Paxil Fraud Case May Spur Congressional, FDA Action – Schering Exec

Pressure is growing for greater disclosure of study results, which may shift industry R&D, Schering compliance VP Saunders says. Former DoJ attorney Bentivoglio suggests that disclosure requirements would include cost-effectiveness data.